Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab.

Autor:	Todoroki T; Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Takeuchi J; Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan., Ota H; Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Nakano Y; Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Sajiki AF; Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Nakamura K; Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Kaneko H; Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Nishiguchi KM; Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Jazyk:	angličtina
Zdroj:	Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2024 Sep 03; Vol. 65 (11), pp. 15.
DOI:	10.1167/iovs.65.11.15
Abstrakt:	Purpose: To examine the changes in aqueous humor cytokine levels and clinical outcomes of switching from aflibercept to faricimab in eyes with neovascular age-related macular degeneration (nAMD). Methods: Fifty-four eyes of 54 patients with AMD undergoing treatment with aflibercept under a treat-and-extend (TAE) regimen were switched to faricimab and studied prospectively. Best-corrected visual acuity (BCVA; in logarithm of the minimum angle of resolution), central retinal thickness (CRT), central choroidal thickness (CCT), and exudative status were analyzed using optical coherence tomography. Aqueous humor was collected before and after the switch, and angiopoietin-2 (Ang-2), placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) A levels were measured. Results: After switching from aflibercept to faricimab, exudative changes improved in 28 eyes (52%), remained stable in eight eyes (15%), and worsened in 18 eyes (33%). BCVA changed from 0.27 ± 0.31 to 0.26 ± 0.29 (P = 0.46), CRT decreased from 306.2 ± 147.5 µm to 278.6 ± 100.4 µm (P = 0.11), and CCT changed from 189.5 ± 92.8 µm to 186.8 ± 93.9 µm (P = 0.21). VEGF-A levels were below the detection sensitivity in many cases throughout the pre- and post-switching periods. Ang-2 significantly decreased from 23.8 ± 23.5 pg/mL to 16.4 ± 21.9 pg/mL (P < 0.001), and PlGF significantly increased from 0.86 ± 0.85 pg/mL to 1.72 ± 1.39 pg/mL (P < 0.001). Conclusions: Switching from aflibercept to faricimab in patients with nAMD may not only suppress VEGF-A but also Ang-2 and reduce exudative changes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu